Patient education would aid compliance

Article

To help improve compliance, patients should be made aware of what a normal intraocular pressure (IOP) is and be informed of their own at each visit to their ophthalmologist, according to Rohit Arora and colleagues from the North Middlesex Hospital, UK.

To help improve compliance, patients should be made aware of what a normal intraocular pressure (IOP) is and be informed of their own at each visit to their ophthalmologist, according to Rohit Arora and colleagues from the North Middlesex Hospital, UK.

In their study, a structured questionnaire was completed by 100 patients attending a glaucoma clinic with chronic open angle glaucoma and ocular hypertension. Questions related to field defects, IOP, treatment and compliance. Their aim was to test patients' knowledge of the condition and therapy and to relate this to treatment compliance.

The investigators found that 13% of patients were unaware that they had glaucoma, however, 87% were aware that the disease has a very serious effect on vision. Forty-seven percent were able to accurately remember the name of their drops, 30% had an appropriate idea but 23% had no idea.

In terms of compliance, 18% depended on family members for the drops, 53% claimed full compliance, 14% admitted to forgetting their drops once in every 15 days, 14% would forget once a month and 20% would forget once in every six months. The main causes of non-compliance were holidays and general forgetfulness.

A significant number, 87%, had no idea about their own IOP and about the pressure range of a normal eye, whilst 80% did not understand the technique or relevance of the field tests. Sixty-four percent were unaware of alternative treatment options and 73% did not know of the existence of helplines and societies.

The team concluded from the study that patients needed to be further educated about the nature of their disease as this would serve to enhance compliance.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.